Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-179,180
Closed -$5.49M 816
2015
Q4
$5.49M Hold
179,180
0.12% 134
2015
Q3
$5.34M Sell
179,180
-527,000
-75% -$16.9M 0.12% 135
2015
Q2
$22.5M Buy
+706,180
New +$23M 0.45% 43

Other funds holding PFE

Scotia Capital's PFE Position: Q1 2026 in Review

Scotia Capital reduced its Pfizer (PFE) stake by 3.8% in Q1 2026, selling an estimated $1.1M and leaving 1,058,826 shares worth $29.7M. The position accounts for 0.12% of the portfolio, ranked #104.

Scotia Capital first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $126M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Scotia Capital held 1,058,826 shares of Pfizer worth $29.7M as of Q1 2026.
  • Scotia Capital sold 41,315 Pfizer shares in Q1 2026, an estimated $1.1M.
  • Pfizer made up 0.12% of Scotia Capital's portfolio in Q1 2026, its #104 holding.
  • Scotia Capital first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's Pfizer position peaked at $126M in Q4 2021.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.